Keywords: tibotec, intelence, cuts, hiv, load, weeks, new
Tibotec's Intelence cuts HIV load at 48 weeks
Article | 18 February 2008
New data shows that, at 48 weeks, significantly more treatment-experienced adults with HIV-1 resistant to non-nucleoside reverse transcriptase inhibitors and protease ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
